SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • December 27th, 2022 • Priveterra Acquisition Corp. • Blank checks • California
Contract Type FiledDecember 27th, 2022 Company Industry JurisdictionThis Settlement and License Agreement (“Agreement”) made and entered into as of June 21, 2021 (the “Effective Date”), by and between, on the one hand Medytox, Inc. (“Medytox”) a company duly organized and existing under the laws of South Korea, having its principal office at 78 Gangni 1-gil Ochang-up Cheongwon-gu Cheongju-si North Chungcheong 28126, Republic of South Korea, and, on the other hand, AEON Biopharma, Inc., (“AEON”) a company duly organized and existing under the laws of Delaware, having its principal office at 4040 MacArthur Boulevard, Suite 260, Newport Beach, CA 92660 (each individually a “Party,” and collectively the “Parties”).
LICENSE & SUPPLY AGREEMENTSupply Agreement • December 27th, 2022 • Priveterra Acquisition Corp. • Blank checks
Contract Type FiledDecember 27th, 2022 Company IndustryTHIS LICENSE AND SUPPLY AGREEMENT (hereinafter this “Agreement”) is entered into this 20th day of December, 2019 (the “Effective Date”), by and between Daewoong Pharmaceutical Co., Ltd, a corporation organized and existing under the laws of the Republic of Korea, having its main office at Bongeunsaro 114-gil 12, Gangnam-gu, Seoul 06170 (hereinafter “DAEWOONG”); and AEON Biopharma, Inc., a corporation organized and existing under the laws of Delaware, United States, having its main office at 4040 MacArthur Blvd, Newport Beach, CA, USA 92660 (hereinafter “AEON”).
EMPLOYMENT AGREEMENTEmployment Agreement • December 27th, 2022 • Priveterra Acquisition Corp. • Blank checks • California
Contract Type FiledDecember 27th, 2022 Company Industry JurisdictionThis Employment Agreement is between Alphaeon Corporation, a Delaware corporation (“Alphaeon”), and AEON Biopharma, Inc., a Delaware Corporation and a wholly- owned subsidiary of Alphaeon (“AEON”) (collectively, the “Company”), and Marc Forth, an individual (“Employee”). This Agreement is entered into on May 7, 2019, and Employee shall commence employment with the Company on May 28, 2019 (“Start Date”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • December 27th, 2022 • Priveterra Acquisition Corp. • Blank checks • California
Contract Type FiledDecember 27th, 2022 Company Industry JurisdictionThis Executive Employment Agreement (this “Agreement”) is between AEON Biopharma, Inc., a Delaware corporation (the “Company”), and Chris Carr, an individual (“Employee”). This Agreement is entered into effective as of September 23, 2019 (the “Effective Date”).
AEON BIOPHARMA, INC. FIRST AMENDMENT TO THE SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • December 27th, 2022 • Priveterra Acquisition Corp. • Blank checks • California
Contract Type FiledDecember 27th, 2022 Company Industry JurisdictionThis First Amendment to the Settlement and License Agreement (this “Amendment”), is made and entered into as of May 5, 2022, by and between AEON Biopharma, Inc., a Delaware corporation (the “Company”), and Medytox, Inc., a company organized under the laws of South Korea (“Medytox”).
AEON BIOPHARMA, INC. FIRST AMENDMENT TO THE LICENSE AND SUPPLY AGREEMENTLicense and Supply Agreement • December 27th, 2022 • Priveterra Acquisition Corp. • Blank checks • New York
Contract Type FiledDecember 27th, 2022 Company Industry JurisdictionThis First Amendment to the License and Supply Agreement (this “Amendment”), is made and entered into as of July 29, 2022, by and between AEON Biopharma, Inc., a Delaware corporation (the “AEON”), and Daewoong Pharmaceutical Co., Ltd, a corporation organized and existing under the laws of the Republic of Korea (“Daewoong”).